Iovance Biotherapeutics (NASDAQ:IOVA) Issues Earnings Results, Beats Estimates By $0.04 EPS

Iovance Biotherapeutics (NASDAQ:IOVA) issued its earnings results on Thursday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04, FiscalAI reports. Iovance Biotherapeutics had a negative return on equity of 30.68% and a negative net margin of 58.20%. The company had revenue of $121.47 million during the quarter, compared to analyst estimates of $115.98 million. The business’s revenue for the quarter was up 64.8% compared to the same quarter last year.

Here are the key takeaways from Iovance Biotherapeutics’ conference call:

• Iovance reported record third-quarter revenue of approximately $122 million, up 80% year over year, including about $102 million from AMTAGVI; it reaffirmed 2026 revenue guidance of $410 million–$420 million. The company has treated more than 1,000 commercial patients and expects at least 110 authorized treatment centers by year-end.
• Gross margin reached a record 60%, operating expenses were managed tightly, and Iovance ended the quarter with approximately $382 million in cash, which it expects to fund operations well into 2029. Management said it is moving toward profitability but did not provide a timeline.
• In previously treated non-squamous metastatic lung cancer, lifileucel showed a 24.6% response rate among 69 patients; a biomarker-enriched subgroup had a 59.1% response rate. Iovance plans an sBLA submission in 2027 and is starting a prospective biomarker-selected study, though the findings remain investigational.
• Updated soft tissue sarcoma results showed a 55.6% response rate in five of nine patients with UPS or DDLPS, including two responses ongoing beyond a year. The registrational SARATOGA trial is enrolling, with submissions planned for 2028 or 2029.
• In a phase II frontline melanoma cohort, lifileucel plus pembrolizumab produced a 62.5% response rate, including complete responses in 29.2% of patients; median overall survival had not been reached after more than four years of follow-up. The phase III TILVANCE-301 trial is enrolling to support a potential frontline approval.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA traded up $0.30 during mid-day trading on Friday, hitting $8.04. The company’s stock had a trading volume of 12,935,434 shares, compared to its average volume of 15,654,120. Iovance Biotherapeutics has a 1 year low of $2.08 and a 1 year high of $15.37. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of -15.17 and a beta of 0.88. The business’s fifty day moving average is $11.37 and its two-hundred day moving average is $5.97.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IOVA. Barclays increased their price objective on Iovance Biotherapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Friday. Citizens Jmp lifted their target price on Iovance Biotherapeutics from $8.00 to $12.00 and gave the stock a “market outperform” rating in a report on Friday. HC Wainwright lifted their target price on Iovance Biotherapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, September 29th. TD Cowen upped their target price on Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, August 24th. Finally, Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Iovance Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $13.80.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
• Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
• Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
• Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.